This site is intended for U.S. Healthcare Professionals
Please orient your device into the portrait position to return to the site.

For Clinically Significant Hypervolemic and Euvolemic Hyponatremia

Serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction

Correction of Serum Sodium
SEE THE EFFICACY DATA FOR PATIENTS WITH HYPONATREMIA INCLUDING:

 

Clinical Safety
SEE THE SAFETY DATA FOR PATIENTS WITH HYPONATREMIA INCLUDING:

Otsuka
Register for Updates

Receive updates on SAMSCA and hyponatremia. Sign up to have the Serum Sodium Sentinel emailed to you.

Otsuka
Videos

Watch patient cases and a video on the mechanism of action of SAMSCA

Otsuka
Visit for Postdischarge Resources

Learn about discharge planning and support

INDICATION AND IMPORTANT SAFETY INFORMATION

 

INDICATION and IMPORTANT SAFETY INFORMATION for SAMSCA® (tolvaptan)

INDICATION

SAMSCA is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH)

Important Limitations

  • Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with SAMSCA
  • It has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients

IMPORTANT SAFETY INFORMATION

SAMSCA should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable

SAMSCA is contraindicated in the following conditions:

  • — Urgent need to raise serum sodium acutely
  • — Inability of the patient to sense or appropriately respond to thirst
  • — Hypovolemic hyponatremia
  • — Concomitant use of strong CYP 3A inhibitors
  • — Anuric patients
  • — Hypersensitivity (e.g. anaphylactic shock, rash generalized) to tolvaptan or its components
  • Too Rapid Correction of Serum Sodium Can Cause Serious Neurologic Sequelae – During initiation and after titration monitor patients to assess serum sodium concentrations and neurologic status. Subjects with SIADH or very low baseline serum sodium concentrations may be at greater risk for too-rapid correction of serum sodium. In patients receiving SAMSCA who develop too rapid a rise in serum sodium, discontinue or interrupt treatment with SAMSCA and consider administration of hypotonic fluid. Fluid restriction during the first 24 hours with SAMSCA may increase the likelihood of overly-rapid correction of serum sodium, and should generally be avoided
  • Liver Injury – SAMSCA can cause serious and potentially fatal liver injury. In a placebo-controlled and open-label extension study of chronically administered tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD), cases of serious liver injury attributed to tolvaptan were observed. Avoid use in patients with underlying liver disease, including cirrhosis, because the ability to recover may be impaired.  Limit duration of therapy with SAMSCA to 30 days. SAMSCA is not approved for use in ADPKD
  • Dehydration and Hypovolemia – In patients who develop medically significant signs or symptoms of hypovolemia, discontinuation is recommended. Dehydration and hypovolemia can occur, especially in potentially volume-depleted patients receiving diuretics or those who are fluid restricted
  • Co-administration With Hypertonic Saline – Not recommended
  • Other Drugs Affecting Exposure to SAMSCA
    • CYP 3A Inhibitors – Do not use with strong inhibitors of CYP 3A; avoid concomitant use with moderate CYP 3A inhibitors
    • CYP 3A Inducers – Avoid concomitant use with CYP 3A inducers. If co-administered, the dose of SAMSCA may need to be increased
    • P-gp Inhibitors – The dose of SAMSCA may have to be reduced if co-administered with P-gp inhibitors
  • Hyperkalemia or Drugs that Increase Serum Potassium – Monitor serum potassium levels in patients with a serum potassium >5 mEq/L and in patients receiving drugs known to increase serum potassium levels

Pregnancy and Nursing Mothers – SAMSCA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because many drugs are excreted into human milk and because of the potential for serious adverse reactions in nursing infants from SAMSCA, a decision should be made to discontinue nursing or SAMSCA, taking into consideration the importance of SAMSCA to the mother

Adverse Reactions – The most common adverse reactions (SAMSCA incidence ≥5% more than placebo, respectively): thirst (16% vs 5%), dry mouth (13% vs 4%), asthenia (9% vs 4%), constipation (7% vs 2%), pollakiuria or polyuria (11% vs 3%) and hyperglycemia (6% vs 1%)

Gastrointestinal Bleeding in Patients with Cirrhosis – In patients with cirrhosis in the hyponatremia trials, GI bleeding was reported in 10% of tolvaptan-treated patients vs 2% for placebo

Please see FULL PRESCRIBING INFORMATION, including Boxed WARNING

Tell a Colleague

Email this page to a colleague.

All fields are required.

​​​​​

Your Name